Results 21 to 30 of about 71,002 (280)
Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma [PDF]
Current Opinion in Oncology, 2014 In 2012, two publications revealed a particular sensitivity of Ewing sarcoma cells to the inhibition of poly(ADP-ribose) polymerase (PARP). This review updates the reader on PARP function, the development of PARP inhibitors (PARPi) and the evidence for targeting PARP in Ewing sarcoma.
Vormoor, Britta, Curtin, Nicola J.
openaire +2 more sources
Inhibition of efflux transporters by poly ADP‐ribose polymerase inhibitors
Basic & Clinical Pharmacology & Toxicology, 2023 AbstractPoly ADP‐ribose polymerase (PARP) inhibitors have been approved for the treatment of various cancers. They share a similar mechanism of action but have differences in pharmacokinetic characteristics and potential for drug–drug interactions (DDI).
Feng Deng +3 more
openaire +3 more sources
Frontiers in Oncology, 2021 BackgroundPoly ADP-ribose glycohydrolase (PARG) is responsible for the catabolism of PARP-synthesized PAR to free ADP-ribose. Inhibition of PARG leads to DNA repair interruption and consequently induces cell death.
Emad Matanes +19 more
doaj +1 more source
Chromosomal instability syndromes are sensitive to poly ADP-ribose polymerase inhibitors
Haematologica, 2008 Poly ADP-ribose polymerase inhibitors have been shown to target cells with homologous recombination DNA repair defects. We report that poly ADP-ribose polymerase inhibitors induces apoptosis in cells deficient in other key DNA repair components ...
Terry J. Gaymes +3 more
doaj +1 more source
The potential role and application of PARP inhibitors in cancer treatment [PDF]
, 2009 Background: Since many anti-cancer agents act by inflicting DNA damage on tumour cells, there is increasing interest in the use of inhibitors of DNA repair to increase the cytotoxicity of these agents.
Chalmers, Anthony J
core +2 more sources
Structural modeling of NAD+ binding modes to PARP-1
Вавиловский журнал генетики и селекции, 2017 The nuclear protein poly (ADP-ribose) polymerase-1 (PARP-1) plays an important role in the signaling and repair of DNA. PARP-1 catalyses covalent binding of poly (ADP-ribose) polymers with itself as well as with other acceptor proteins using NAD+ as a ...
N. V. Ivanisenko +2 more
doaj +1 more source
ARH Family of ADP-Ribose-Acceptor Hydrolases
Cells, 2022 The ARH family of ADP-ribose-acceptor hydrolases consists of three 39-kDa members (ARH1-3), with similarities in amino acid sequence. ARH1 was identified based on its ability to cleave ADP-ribosyl-arginine synthesized by cholera toxin.
Hiroko Ishiwata-Endo +6 more
doaj +1 more source
Structure, function and inhibition of poly(ADP-ribose)polymerase, member 14 (PARP14) [PDF]
, 2018 Poly(ADP-ribose)polymerase, member 14 (PARP14, alternatively named ARTD8, BAL2, and COAST6) is an intracellular mono(ADP-ribosyl) transferase. PARP14 transfers a negatively charged ADP-ribose unit from a donor NAD+ molecule onto a target protein, post ...
Levonis, Stephan M +3 more
core +1 more source
Human PARP1 substrates and regulators of its catalytic activity: An updated overview
Frontiers in Pharmacology, 2023 Poly (ADP-ribose) polymerase 1 (PARP1) is a key DNA damage sensor that is recruited to damaged sites after DNA strand breaks to initiate DNA repair. This is achieved by catalyzing attachment of ADP-ribose moieties, which are donated from NAD+, on the ...
Tao Zhu +5 more
doaj +1 more source
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. [PDF]
, 2017 Veliparib combined with carboplatin (VC) was an experimental regimen evaluated in the biomarker-rich neoadjuvant I-SPY 2 trial for breast cancer. VC showed improved efficacy in the triple negative signature.
Berry, Don +20 more
core +2 more sources